p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10382-10392

  Vici, Patrizia ^a   Sperati, Francesca ^a   Maugeri Saccà, Marcello ^a   Melucci, Elisa ^a   Benedetto, Anna Di ^a   Lauro, Luigi Di ^a   Pizzuti, Laura ^a   Sergi, Domenico ^a   Terrenato, Irene ^a   Esposito, Luca ^b   Iannuzzi, Carmelina Antonella ^b   Pasquale, Raffaella ^c   Botti, Claudio ^a   Fuhrman, Barbara ^d   Giordano, Antonio ^e   Mottolese, Marcella ^a   Barba, Maddalena ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CROM Center of Oncology Research Mercogliano   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e Temple University   (United States)

Author keywords

Fasting glucose; HER2 positive breast cancer; p53 status; Trastuzumab

Indexed keywords

GLUCOSE; PROTEIN P53; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; MONOCLONAL ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CODON; DISEASE FREE SURVIVAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; SOMATIC MUTATION; SURVIVAL RATE; ANALYSIS; BREAST NEOPLASMS; CARCINOGENESIS; CARCINOMA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; BREAST NEOPLASMS; CARCINOGENESIS; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; EFFECT MODIFIER, EPIDEMIOLOGIC; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TRASTUZUMAB; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84916897470     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2060     Document Type: Article

References (43)

1. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992, 358:15-16.
2. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134: 703-707.
3. Kondoh H, Leonart M, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005; 65: 177-185.
4. Maddocks OD, Vousden K. Metabolic regulation by p53. J Mol Med (Berl). 2011; 89: 237-245.
5. Nahta R, O'Regan R. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer. 2010; 10 (Suppl 3): S72-78.
6. Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit. 2002; 8: BR521-PR526.
7. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001; 93: 1852-1857.
8. Larsson SC, Mantzoros C, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007; 121: 856-862.
9. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293: 194-202.
10. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007; 30: 561-567.
11. Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, Caolo G, Mottolese M, Botti G, Terrenato I, Vici P, Serpico D, Giordano A, et al. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol. 2012; 23: 1838-1845.
12. Minicozzi P, Berrino F, Sebastiani F, Falcini F, Vattiato R, Cioccoloni F, Calagreti G, Fusco M, Vitale MF, Tumino R, Sigona A, Budroni M, Cesaraccio R, et al. High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease. Eur J Cancer. 2013; 49: 3881-3888.
13. Contiero P, Berrino F, Tagliabue G, Mastroianni A, Di Mauro MG, Fabiano S, Annulli M, Muti P. Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study. Breast Cancer Res Treat. 2013; 138: 951-959.
14. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364: 829-884.
15. Langerod A, Zaho H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007; 9: R30.
16. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869-10874.
17. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005; 102: 13550-13555.
18. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009; 9: 701-713.
19. Köstler WJ, Brodowicz T, Hudelist G, Rudas M, Horvat R, Steger GG, Singer CF, Attems J, Rabitsch W, Fakhrai N, Elandt K, Wiltschke C, Hejna M, et al. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status. J Cancer Res Clin Oncol. 2005; 131: 420-428.
20. Hall PA, Lane D. p53 in tumour pathology: can we trust immunohistochemistry? Revisited!. J Pathol. 1994; 172: 1-4.
21. Lepelley P, Preudhomme C, Vanrumbeke M, Quesnel B, Cosson A, Fenaux P. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistryand DNA analysis. Leukemia. 1994; 8: 1342-1349.
22. Marks JR, DavidoffA, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991; 51: 2979-2984.
23. Casey G, Lopez M, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996; 13: 1971-1981.
24. Bedard PL, Hansen A, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013; 501: 355-364.
25. The Cancer Genome Atalas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
26. Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS, Ogino S. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer. 2012; 131: 1169-1178.
27. Robertson R, Zhou H, Zhang T, Harmon JS. Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. Cell Biochem Biophys. 2007; 48: 139-146.
28. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009; 9: 563-575.
29. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408: 307-310.
30. Duan X, Ponomareva L, Veeranki S, Choubey D. IFI16 induction by glucose restriction in human fibroblasts contributes to autophagy through activation of the ATM/AMPK/p53 pathway. PLoS One. 2011; 6: e19532.
31. Zajkowicz A, Rusin M. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases. Mech Ageing Dev. 2011; 132: 543-551.
32. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci. 2005; 102: 8204-8209.
33. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 2008; 134: 451-460.
34. Leontieva OV, Novototskaya LR, Paszkiewicz GM, Komarova EA, Gudkov AV, Blagosklonny MV. Dysregulation of the mTOR pathway in p53-deficient mice. Cancer Biol Ther. 2013 1;14:1182-8
35. Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? Aging (Albany NY). 2012; 4:450-5.
36. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A. 2010; 107:9660-4.
37. Levine AJ, Harris CR, Puzio-Kuter AM. The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson Disease pathway. Oncotarget. 2012 ;3:1301-7.
38. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV, Antoch MP. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY). 2012;4:715-22.
39. Di Palma S, Collins N, Bilous M, Sapino A, Mottolese M, Kapranos N, Schmitt F, Isola J. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol. 2008; 61: 757-760.
40. American Diabetes Association. Clinical Practice Recommendations. Diabetes Care. 2008; 31(Suppl 1): S1-108.
41. WolffAC, Hammomd M, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, et al. American Society Of Clinical Oncology/College Of American Pathologists Guideline Recommendations For Human Epidermal Growth Factor Receptor 2 Testing In Breast Cancer. Arch Pathol Lab Med. 2007; 131: 18-43.
42. WolffAC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Barlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013; 31: 3997-4013.
43. Seeger A, Kolbl H, Petry IB, Gebhard S, Battista MJ, Böhm D, Steiner E. p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer. Gynecol Oncol. 2012; 125: 200-207.